X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ELDER PHARMA AJANTA PHARMA/
ELDER PHARMA
 
P/E (TTM) x 24.5 -0.2 - View Chart
P/BV x 10.1 0.1 10,024.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AJANTA PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ELDER PHARMA
Jun-14
AJANTA PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720380 452.6%   
Low Rs1,103188 586.7%   
Sales per share (Unadj.) Rs194.6491.2 39.6%  
Earnings per share (Unadj.) Rs45.2-3.2 -1,421.3%  
Cash flow per share (Unadj.) Rs50.314.4 349.1%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0376.5 35.1%  
Shares outstanding (eoy) m88.7720.54 432.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.6 1,254.5%   
Avg P/E ratio x31.2-89.3 -35.0%  
P/CF ratio (eoy) x28.119.7 142.4%  
Price / Book Value ratio x10.70.8 1,417.3%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2995,833 2,148.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5702,179 117.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,27510,089 171.2%  
Other income Rs m166257 64.8%   
Total revenues Rs m17,44210,346 168.6%   
Gross profit Rs m5,807-792 -733.3%  
Depreciation Rs m451361 124.7%   
Interest Rs m492,756 1.8%   
Profit before tax Rs m5,474-3,653 -149.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m1,460125 1,166.5%   
Profit after tax Rs m4,014-65 -6,142.5%  
Gross profit margin %33.6-7.8 -428.3%  
Effective tax rate %26.7-3.4 -778.4%   
Net profit margin %23.2-0.6 -3,587.3%  
BALANCE SHEET DATA
Current assets Rs m7,6399,240 82.7%   
Current liabilities Rs m2,7159,998 27.2%   
Net working cap to sales %28.5-7.5 -379.5%  
Current ratio x2.80.9 304.5%  
Inventory Days Days4346 93.3%  
Debtors Days Days7960 131.3%  
Net fixed assets Rs m6,91410,124 68.3%   
Share capital Rs m177206 86.0%   
"Free" reserves Rs m11,4425,582 205.0%   
Net worth Rs m11,7217,734 151.6%   
Long term debt Rs m1494,889 3.0%   
Total assets Rs m14,81422,882 64.7%  
Interest coverage x112.9-0.3 -34,720.5%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x1.20.4 264.5%   
Return on assets %27.411.8 233.2%  
Return on equity %34.2-0.8 -4,052.9%  
Return on capital %46.522.3 208.6%  
Exports to sales %55.13.0 1,814.7%   
Imports to sales %6.00.4 1,406.0%   
Exports (fob) Rs m9,527307 3,107.3%   
Imports (cif) Rs m1,03843 2,407.4%   
Fx inflow Rs m10,422307 3,399.2%   
Fx outflow Rs m1,678125 1,339.3%   
Net fx Rs m8,744181 4,822.7%   
CASH FLOW
From Operations Rs m3,26411,754 27.8%  
From Investments Rs m-2,093-561 373.4%  
From Financial Activity Rs m-1,186-6,762 17.5%  
Net Cashflow Rs m-154,432 -0.3%  

Share Holding

Indian Promoters % 73.8 39.6 186.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 7.5 20.7%  
FIIs % 7.6 16.8 45.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 36.1 47.1%  
Shareholders   20,968 16,479 127.2%  
Pledged promoter(s) holding % 4.4 77.6 5.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  DIVIS LABORATORIES  SUVEN LIFE  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - SUN PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS